期刊文献+

抗肿瘤药拉帕替尼有关物质的合成 被引量:1

Synthesis of related substances of lapatinib
原文传递
导出
摘要 目的合成拉帕替尼的3个有关物质。方法拉帕替尼与5-[4-[[3-氯-4-[(3-氟苯基)甲氧基]苯基]氨基]-6-喹唑啉]-2-呋喃甲醛经还原胺化反应制得有关物质双{{5-{4-{{3-氯-4-[(3-氟苄基)氧基]苯基}氨基}喹唑啉-6-基}呋喃-2-基}甲基}[2-(甲磺酰基)乙基]胺(Ⅰ);在三氟乙酸回流条件下拉帕替尼的醚键发生断裂制得有关物质2-氯-4-{{6-{5-{{[2-(甲磺酰基)乙基]氨基}甲基}呋喃-2-基}喹唑啉-4-基}氨基}苯酚(Ⅱ);以5-[4-[[3-氯-4-[(3-氟苯基)甲氧基]苯基]氨基]-6-喹唑啉]-2-呋喃甲醛为原料,经肟化、还原制得有关物质6-[5-(氨基甲基)呋喃-2-基]-N-{3-氯-4-[(3-氟苄基)氧基]苯基}喹唑啉-4-胺(Ⅲ)。结果与结论有关物质Ⅰ、Ⅱ、Ⅲ的结构经MS、^1H-NM R谱确证,Ⅰ、Ⅱ、Ⅲ可作为拉帕替尼质量控制的杂质对照品。 To perform the quality control of lapatinib,three related substances were prepared.The process impurity bis[[5-[4-[[3-chloro-4-[(3-fluorobenzyl) oxy]phenyl]amino]quinazolin-6-yl]furan-2-yl]methyl][2-(methylsulfonyl) ethyl]amine(Ⅰ) has been directly prepared by reductive amination reaction using lapatinib and 5-[4-[[3-chloro-4-[(3-f1uorophenyl) methoxy]phenyl]amino]-6-quinazolinyl]-2-furaldehyde(2) as starting materials;The degradation impurity 2-chloro-4-[[6-[5-[[[2-(methylsulfonyl) ethyl]amino]methyl]furan-2-yl]quinazolin-4-yl]amino]phenol(Ⅱ) has been prepared in trifluoroacetic acid under reflux conditions,using lapatinib as starting material;The degradation impurity N-[3-ehloro-4-[(3-fluorobenzyl) oxy]phenyl]-6-[5-(amino methyl) furan-2-yl]-4-quinazolinamine(HI) has been prepared through two steps:oximation and reduction from the raw material 2.The structures of three impurities of lapatinib were verified by MS and ~1H-NMR.The three specified impurities can be used as the reference substances of the related substances in the quality control of lapatinib.
出处 《中国药物化学杂志》 CAS CSCD 2016年第3期185-188,共4页 Chinese Journal of Medicinal Chemistry
基金 国家自然科学基金项目(81273373) 上海市科委青年科技英才扬帆计划项目(14YF1412800)
关键词 拉帕替尼 有关物质 合成 lapatinib related substance synthesis
  • 相关文献

参考文献4

二级参考文献15

  • 1FDA Approves Tykerb for Advanced Breast Cancer Patients[ EB/ OL]. FDA News P0744, March 13, 2007. http://www, fda. gov/bbs/topics/N EWS/2007/NEW01586. html.
  • 2Glaxo Smith Kline. Highlights of Prescribing Information:TYKERB (lapatinb) tables [ J/OL ]. http://www, fda. gov/cder/ foi/label/2007 /0220591bl. pdf.
  • 3JOHNSTON S R, I,EARY A. Lapatinib: a novrel EGFR/HER2 tyrosine kinase inhibitor for cancer [ J ] . Drugs 7bday (Barc ), 2006,42(7) :441-453.
  • 4GEYER C E, FORSTER J, LINDQUIST D, et al. Lapatinib plus capecitabine for ltER2-positive advanced breast cancer [ J ]. N Engl J Med,2006,355 (26) :2733-2743.
  • 5NAHTA R, YUAN L X, DU Y, et al. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulinlike growth factor I signaling [ J ]. Mol Cancer Tiger,2007,6 (2) : 667-674.
  • 6KONECNY G E, PEGRAM M D, VENKATESAN N, et al. Activity of the dual kinase inhibitor lapatinib ( GW572016 ) against HER-2-overexpressing and trastuzumab-treated breast cancer cells [ J ]. Cancer Res ,2006,66 ( 3 ) : 1630-1639.
  • 7KELLY H, GRAHAM M, HUMES E, et al. Delivery of a healthy baby after first-trimester maternal exposure to lapatinlb [ J ]. Clln Breast Cancer,200,7(4) :339-341.
  • 8U S FDA.FDA approves Tykerb for advanced breast cancer patients[EB/OL].[2007-06-25].http://www.fda.gov/bbs/topics/NEWS/2007/NEW01586.html.
  • 9RUBIN S.Lapatinib compounds for the treatment of breast cancer that has metastasized to the brain; WO,2006/066267[P].2006-06-22.
  • 10MAUNG K,O'SHAUGHNESSY J A.Inhibition of ErbB1 and ErbB2 by lapatinib ditosylate,a dual kinase inhibitor:Promising activity in pretreated advanced breast cancer[J].Clin Breast Cancer,2004,6:398-400.

共引文献10

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部